| |
|
|
|
|
| |
|
|
 |
Il rischio cardiovascolare |
|
|
pag 27
BIBLIOGRAFIA
1. Progetto Cuore. Sito internet: www.cuore.iss.it
2. European Journal of Cardiovascular Prevention and Rehabilitation 2003; 10:S1-S10
3. National Cholesterol Education Program III. Circulation 2004; 110:227
4. Broedl UC et al. J Gen Intern Med 2003; 18:190
5. Studio 4 S. Lancet 1994; 344:1383
6. Studio CARE. N Eng J Med 1996; 335:1001
7. Studio LIPID. N Engl J Med 1998; 339:1349
8. Studio WOSCOPS. N Engl J Med 1995; 333:1301
9. Studio AFCAPS-TexCAPS. JAMA 1998; 279:1615
10.Studio PROSPER. Lancet 2002; 360:1623
11.Studio ALLHAT-LLT. JAMA 2002; 288:2998
12.Studio ASCOT-LLA. Lancet 2003; 361:1149
13.Studio HPS. Lancet 2002;360:7
14.Studio GREACE. Cur Med Res Opin 2002;18:220
15.Therapeutic Letter n. 48. Sito internet: http://www.ti.ubc.ca
16.Studio PROVE-IT. N Engl J Med 2004;350:1562
17.Studio REVERSAL. JAMA 2004; 291:1071
18.Studio CARDS.Lancet 2004; 364:685
19.J Am Geriatr Soc 2003; 51:930
20.J Am Geriatr Soc 2003; 51:991
21.Am J Med 2003; 115:265
22.BMJ 2002; 324:71
23.USPSTF. Ann Inter Med 2002; 136:157
24.Clinical Evidence. Prima Ed.Italiana 2001, pag. 65
25.Lauer SM. N Engl J Med 2002; 346:1468
26.Studio HOPE. N Engl J Med 2000; 342:145
27.Studio EUROPA.Lancet 2003; 362:782
28.JAMA 2002; 288:2015, 2042
29.BMJ 2003; 326:131
30.Studio GISSI-PREVENZIONE. Lancet 1999; 354:447
31.Avins AL et al. Arch Intern Med 2000; 160:1937
32.R Padwal et al. International Journal of Obesity 2003 27: 1437-1446.
33.Effective Health Care 1998 Feb; Vol. 4, n. 1
34.Lenzer J. BMJ 2004;329:759
35.Ridker PM et al. A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women. N Engl J Med 2005 Mar 31; 352:1293-1304
36. La Rosa JC et al for the Treating to New Targets (TNT) Investigators. Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. N Engl J Med 2005;352:1425-35
37. Rosengren A et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11 119 cases and 13 648 controls from 52 countries (the INTERHEART study): case-control study. Lancet 2004 Sept 11; 364: 953-62
38.Wittstein IS et al. Neurohumoral Features of Myocardial Stunning Due to Sudden Emotional Stress. N Engl J Med 2005 Feb 10; 352:539-548
39.Rozanski A et al. J Am Coll Cardiol 2005 Mar 1; 45:637-651.
40. Austin MA et al. Am J Cardiol. 1998 Feb 26;81(4A):7B-12B
41.Studer M et al. Effect of Different Antilipidemic Agents and Diets on Mortality . A Systematic Review. Arch Intern Med. 2005 Apr 11; 165:725-730.
42.Schupf N et al.Relationship between plasma lipids and all-cause mortality in nondemented elderly. J Am Geriatr Soc 2005;53: 219-26
43.Birjmohun RS, et al. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol January 18, 2005;45:185-97.
44. Lewis SJ et al. Meta-analysis of MTHFR 677 CT polymorphism and coronary heart disease :does totaly of evidence support causal role for homocysteine and preventive potential of folate ? BMJ 2005 Nov 5; 331:1053
45. Matsuzaki M et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Primary prevention cohort study of the Japan Lipid Intervention Trial. Circulation 2002; 66: 1087-1095
46. Pedersen TR et al. for the Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group. High-dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction. The IDEAL Study. JAMA 2005 Nov 16; 294:2437-2445
47. Pignone M et al. Aspirin, Statins, or Both Drugs for the Primary Prevention of Coronary Heart Disease Events in Men: A Cost–Utility Analysis
Ann Intern Med 2006 Mar 7; 144:326-336
48. Foody JM et al. Hydroxymethylglutaryl-CoA Reductase Inhibitors in Older Persons with Acute Myocardial Infarction: Evidence for an Age–Statin Interaction. J Am Geriatr Soc 2006 Mar; 54:421
49.The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. The Lancet 2005 Nov 26; 366:1849-1861
50. Toole J.F. et al. Lowering Homocysteine in Patients With Ischemic Stroke to Prevent Recurrent Stroke, Myocardial Infarction, and Death
The Vitamin Intervention for Stroke Prevention (VISP) Randomized Controlled Trial . JAMA 2004 Feb 4; 291:565-575.
51. The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006 Apr 13; 354:1567-77.
52. Bøna KH et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006 Apr 13; 354:1578-88
53. Wilt TJ et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 2004; 164:1427
54. Garg A. Statins for all patients with type 2 diabetes: not so soon. Lancet 2004; 364:641
55. Costa J et al. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials
BMJ 2006 May 13; 332: 1115-1124
56. Zhou Z, et al. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J February 2006;151:273-81.
57. Knopp RH et al. Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN). Diabetes Care 2006 Jul; 29:1478-1485
58. Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysys of data from 90056 partecipants in 14 randomised trials of statins. Lancet 2005; 366:1267-1278
59. Drug and Therapeutics Bulleti. Edizione Italiana. Anno 2006, numero 8 (agosto), pagg. 57-60
60. Thavendiranathan P et al. Primary Prevention of Cardiovascular Diseases With Statin Therapy. A Meta-analysis of Randomized Controlled Trials. Arch Intern Med. 2006 Nov 27;166:2307-2313
61. Bazzano LA et al. Effect of Folic Acid Supplementation on Risk of Cardiovascular Diseases. A Meta-analysis of Randomized Controlled Trials. JAMA. 2006 Dec 13;296:2720-2726.
62. Folsom AR et al. An Assessment of Incremental Coronary Risk Prediction Using C-Reactive Protein and Other Novel Risk Markers
The Atherosclerosis Risk in Communities Study. Arch Intern Med. 2006;166:1368-1373.
63. Wang TJ et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006 Dec 21; 355:2631-9
64. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet 2008 Jan 12; 371:117-125.
65. Ridker PM et al. for the JUPITER Study Group. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med 2008 Nov 20; 359:2195-2207
66. Aspirin for the Prevention of Cardiovascular Disease: U.S. Preventive Services Task Force Recommendation Statement. U.S. Preventive Services Task Force. Ann Intern Med 2009 Mar 17; 150: 396-404
67. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
Lancet 2009 May 30; 373:1849-1860
68. De Berardis G, Sacco M, Strippoli GFM, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: Meta-analysis of randomised controlled trials. BMJ 2009; DOI:10.1136/bmj.b4531.
|
|
|
|
|
|
|
|
2004 - 2024 © Pillole.org Reg. T. di Roma 2/06 |
 |
 |
ore 07:43 | 1286847 accessi| utenti in linea:
22949
Realizzato con ASP-Nuke 2.0.5
|
